| pubmed-article:19729831 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19729831 | lifeskim:mentions | umls-concept:C0007124 | lld:lifeskim |
| pubmed-article:19729831 | lifeskim:mentions | umls-concept:C0006141 | lld:lifeskim |
| pubmed-article:19729831 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:19729831 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:19729831 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:19729831 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:19729831 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:19729831 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:19729831 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:19729831 | pubmed:dateCreated | 2009-9-4 | lld:pubmed |
| pubmed-article:19729831 | pubmed:abstractText | The protein 14-3-3sigma is involved in the regulation of cellular processes such as apoptosis, cell cycle progression and proliferation. Disruption of protein expression has been implicated in a number of malignancies. Here we examine the expression pattern of 14-3-3sigma in breast cancer and specifically consider whether expression in ductal carcinoma in situ (DCIS) lesions is predictive of disease outcome. We examined 14-3-3sigma protein expression and localization using immunohistochemical staining on a high-density tissue microarray consisting of 157 invasive breast cancer patients. Statistical analyses were used to assess the correlation of 14-3-3sigma expression with clinico-pathological parameters and patient outcome. We observed a statistically significant increase in 14-3-3sigma protein expression in ductal hyperplasia, DCIS, and invasive ductal carcinoma (IDC) as compared normal glandular epithelium. In IDC, lower expression of 14-3-3sigma tended to predicted poorer survival time while in DCIS lesions, there was a stronger correlation between relatively higher levels of 14-3-3sigma predicting shorter survival time. Further, of patients who had concurrent DCIS and IDC lesions, those that exhibited a decrease of 14-3-3sigma expression from DCIS to IDC had significantly shorter survival time. Our findings indicate that 14-3-3sigma expression may be a useful prognostic indicator for survival in patients with breast cancer with an elevated 14-3-3sigma in earlier disease predicting a less favorable disease outcome. To our knowledge this is the first published study associating 14-3-3sigma protein expression with breast cancer survival. | lld:pubmed |
| pubmed-article:19729831 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19729831 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19729831 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19729831 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19729831 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19729831 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19729831 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19729831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19729831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19729831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19729831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19729831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19729831 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19729831 | pubmed:issn | 1875-8592 | lld:pubmed |
| pubmed-article:19729831 | pubmed:author | pubmed-author:BonavidaBenja... | lld:pubmed |
| pubmed-article:19729831 | pubmed:author | pubmed-author:GoodglickLeeL | lld:pubmed |
| pubmed-article:19729831 | pubmed:author | pubmed-author:BoseShikhaS | lld:pubmed |
| pubmed-article:19729831 | pubmed:author | pubmed-author:SeligsonDavid... | lld:pubmed |
| pubmed-article:19729831 | pubmed:author | pubmed-author:HorvathSteveS | lld:pubmed |
| pubmed-article:19729831 | pubmed:author | pubmed-author:LiAiA | lld:pubmed |
| pubmed-article:19729831 | pubmed:author | pubmed-author:SulurGiriG | lld:pubmed |
| pubmed-article:19729831 | pubmed:author | pubmed-author:ChiaDavidD | lld:pubmed |
| pubmed-article:19729831 | pubmed:author | pubmed-author:ElshimaliYahy... | lld:pubmed |
| pubmed-article:19729831 | pubmed:author | pubmed-author:MahVeiV | lld:pubmed |
| pubmed-article:19729831 | pubmed:author | pubmed-author:YoonNam KNK | lld:pubmed |
| pubmed-article:19729831 | pubmed:author | pubmed-author:MareshErinE | lld:pubmed |
| pubmed-article:19729831 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19729831 | pubmed:volume | 5 | lld:pubmed |
| pubmed-article:19729831 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19729831 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19729831 | pubmed:pagination | 215-24 | lld:pubmed |
| pubmed-article:19729831 | pubmed:dateRevised | 2011-9-26 | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:meshHeading | pubmed-meshheading:19729831... | lld:pubmed |
| pubmed-article:19729831 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19729831 | pubmed:articleTitle | Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome. | lld:pubmed |
| pubmed-article:19729831 | pubmed:affiliation | Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1747, USA. | lld:pubmed |
| pubmed-article:19729831 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19729831 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| entrez-gene:2810 | entrezgene:pubmed | pubmed-article:19729831 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19729831 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19729831 | lld:pubmed |
